- $877.15m
- $371.52m
- $67.48m
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Kura Oncology & Kyowa Kirin Announce Positive KOMZIFTI Combination Data for acute myeloid
Brief: First U.S. Commercial Sale Of Komzift Triggers $135 Million Milestone Payment To Kura Oncology
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA
Brief: KOMZIFTI Gets FDA Approval For Adults With Relapsed Or Refractory NPM1-Mutated AML
Kura Oncology rises after US FDA approves its blood cancer therapy
US FDA approves Kura Oncology's blood cancer therapy (updated)
US FDA approves Kura Oncology's blood cancer therapy
Brief: FDA Approves Ziftomenib For Relapsed Or Refractory Acute Myeloid Leukemia With A NPM1 Mutation
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology Q3 net loss widens to $74.1 mln
Brief: Kura Oncology Receives Second $30 Million Development Milestone Payment In Aml Menin Inhibitor Program With Kyowa Kirin
U.S. STOCKS ON THE MOVE-GrafTech, Nextracker, Alpha and Omega, Coinbase
U.S. STOCKS ON THE MOVE-GrafTech, Nextracker, Alpha and Omega
Kura rises on $30 mln milestone payment after first patient dosed in late-stage trial
U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTech
Brief: Kura Oncology Gets $30M Milestone in AML Deal with Kyowa Kirin
Kura rises on $30 mln milestone payment after first patient dosed in late-stage trial